5. Efficacy according to clinically important factors, including type of chemotherapy regimen.

Variables	CBR [% (n/N)]				PFS (95% CI)
	NPCT (n=129)	PBCT (n=91)	P		NPCT (n=129)	PBCT (n=91)	P
DFS, disease-free survival; NPCT, non-platinum-based chemotherapy; PBCT, platinum-based chemotherapy; CBR, clinical benefit rate; PFS, progression-free survival; 95% CI, 95% confidence interval.
Total	48.1 (62/129)	51.6 (47/91)	0.600		6.0 (4.6−7.4)	6.6 (5.1−8.1)	0.907
Age of onset (year)
≤50	53.1 (34/64)	56.5 (35/62)	0.708		6.4 (4.9−7.9)	7.3 (5.9−8.7)	0.950
>50	43.1 (28/65)	41.4 (12/29)	0.878		5.7 (2.3−9.1)	4.5 (1.7−7.3)	0.713
DFS (month)
≤24	31.8 (21/66)	44.9 (31/69)	0.118		4.5 (3.4−5.6)	6.2 (4.4−8.0)	0.333
>24	65.1 (41/63)	72.7 (16/22)	0.511		7.9 (7.0−8.8)	8.6 (0.8−16.4)	0.965
Visceral metastasis	47.4 (27/57)	50.0 (20/40)	0.798		6.0 (4.2−7.8)	6.7 (4.0−9.4)	0.939
Non-visceral metastasis	48.6 (35/72)	52.9 (27/51)	0.636		6.5 (4.7−8.3)	6.6 (3.6−9.6)	0.866
Lung metastasis	48.8 (20/41)	46.7 (14/30)	0.860		6.0 (3.5−8.5)	6.2 (3.0−9.4)	0.687
Liver metastasis	37.5 (9/24)	61.5 (8/13)	0.188		4.0 (2.6−5.4)	7.8 (5.0−10.6)	0.078
Chest wall metastasis	34.8 (8/23)	55.6 (10/18)	0.183		5.0 (2.1−7.9)	6.6 (2.1−11.1)	0.096
Bone metastasis	51.6 (16/31)	55.0 (11/20)	0.813		5.7 (1.3−10.1)	8.0 (6.6−9.4)	0.980
Lymph node metastasis	48.2 (27/56)	48.8 (21/43)	0.951		7.3 (4.9−9.7)	6.2 (4.4−8.0)	0.765